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Haemostasis is a physiological process that stops blood loss at the site 
of injury, while maintaining normal blood flow in the rest of the circu­
lation. This is accomplished in three physiological steps that occur in 
rapid sequence: (i) vasoconstriction; (ii) formation of a platelet plug 
(primary haemostasis); and (iii) stabilisation of clot through cross­link­
ing of insoluble fibrin (secondary haemostasis). The fibrin mesh that is 
incorporated into and around the platelet plug serves to strengthen and 
stabilise the blood clot. Apart from limiting blood loss, the clot allows 
for vessel and tissue repair. Anticoagulant mechanisms regulate the 
coagulation system to ensure formation of a clot that is proportional to 
the injury. A delicate balance between procoagulant and anticoagulant 
systems is critical for proper haemostasis and for avoiding pathological 
bleeding or thrombosis. The clot is finally dissolved by the fibrinolytic 
system, which also performs the function of preventing blood clots in 
healthy blood vessels. 
For the purpose of discussion in this two­part CME series, bleeding 
disorders are divided into two broad categories: (i) inherited (part 1, 
current issue);[1] and (ii) acquired (part 2, forthcoming issue).
Inherited bleeding disorders (IBDs) should be suspected when there 
is a family history of a bleeding disorder or abnormal bleeding during 
early childhood, such as the neonatal period or infancy. However, IBD 
patients may also present for the first time during adulthood.
Investigation of abnormal bleeding requires a comprehensive 
history, thorough physical examination and systematic laboratory 
work­up. For the laboratory work­up, an algorithmic approach is 
included in the article in this edition of CME (Fig. 2).[1] 
To appreciate the rationale for using the various clotting tests 
towards achieving a diagnosis, an understanding of the coagulation 
cascade is necessary. A simplified schematic representation – Fig. 1 
in the article in this issue[1] – is intended to orientate the reader with 
regard to the pathophysiology of the respective bleeding disorders.
The article discusses a wide range of IBDs and provides a diagnostic 
approach and available therapeutic options for the general practitioner. 
Patients diagnosed with a bleeding diathesis should ideally be referred 
to a tertiary healthcare facility such as a haemophilia centre for 
management and follow­up.
von Willebrand disease and haemophilia, being the most common 
IBDs, are discussed in greater detail. However, a comprehensive review 
of the various bleeding disorders with elaborate detail, such as 
pathophysiological mechanisms and genetic defects, is beyond the 
scope of this CME.
There has been significant progress with regard to the treatment 
of haemophilia, where the current standard of care is to prevent 
bleeding by prophylactic infusions of the deficient clotting factor as 
opposed to on­demand infusions following a bleed. This preventive 
strategy that is sure to reduce the hospitalisation and complication 
rates, comes at a cost, which is a limiting factor. Newer technologies 
with development of modified factor VIII products with an extended 
half­life and less immunogenic potential are emerging. With less 
frequent factor infusions, the prospect of prophylactic therapy 
is likely to become more affordable in economically challenged 
environments such as South Africa. This is an exciting yet realistic 
prospect that would allow haemophiliacs to lead almost normal 
lives. For any disease a cure is the ultimate aim, and in this context 
gene therapy has recently emerged as a potential therapeutic option 
for haemophilia B.
The authors are indeed grateful for the opportunity to discuss the 
subject of bleeding disorders, which 
is an important and dynamic sphere 
of coagulation.
N Alli
Department of Molecular 
Medicine and Haematology, 
School of Pathology, Faculty of 
Health Sciences, University of the 
Witwatersrand, Johannesburg, and 
National Health Laboratory Service, 
Johannesburg, South Africa
nazeer.alli@nhls.ac.za
1. Alli N, Vaughan J, Louw S, Schapkaitz E, Mahlangu J. Inherited bleeding disorders. S Afr Med J 
2018;108(1):9­15. DOI:10.7196/SAMJ.2018.v108i1.13020. 
S Afr Med J 2018;108(1):8. DOI:10.7196/SAMJ.2018.v108i1.13019
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
GUEST EDITORIAL
Bleeding disorders (part 1)
